Abstract: | Adrenoceptors beta‐3‐subtype mediate lipolysis and in the search for potential beta‐3‐adrenergic receptors agonists for the treatment of obesity, we designed new arylethanolamines (structures 4, 5 ) and aryloxypropanolamines (structures 6, 7 ) derived from 2(3H)‐benzoxazolone and 2(3H)‐benzothiazolone. |